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ABSTRACT - Cutaneous rash is one of the commonest adverse events associated with lamotrigine. We assessed 
whether the risk is increased in patients receiving concomitant valproate therapy in a population of 103 adult 
patients with intractable epilepsy, who had lamotrigine added to their treatment. Of the 33 patients taking 
valproate, 10 (30%) developed a rash, whilst of the 70 not taking valproate, only 6 (8%) developed a rash. This 
suggests a significantly higher risk of cutaneous rash when starting lamotrigine in patients already taking 
valproate (p<0.02). 
KEY WORDS: allergic skin rash, antiepileptic drugs, lamotrigine, valproate. 
Rash cutâneo com lamotrigina e concomitante uso de valproate, evidências de maior risco 
RESUMO - Rash cutâneo é um dos efeitos adversos mais comuns associados ao início de tratamento com 
lamotrigina, uma nova medicação antiepiléptica. Avaliamos se esse risco é maior em pacientes medicados 
concomitantemente com valproato em 103 pacientes adultos com epilepsia refratária, que tiveram lamotrigina 
adicionada a seu tratamento. Dez dos 33 pacientes (30%) que faziam uso de valproato e 6 (8%) dos 70 pacientes 
que não usaram valproato desenvolveram rash. Isto sugere que existe maior risco de desenvolver rash cutâneo 
quando se adiciona lamotrigina em pacientes em uso de valproato (p<0,02). 
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Cutaneous rash is a well established adverse effect of phenytoin, carbamazepine, and has also 
been reported with lamotrigine (LTG) therapy. It is very rare with valproate (VPA). The overall rate 
of skin rash in patients receiving lamotrigine is approximately 3%There have been suggestions of 
a higher incidence of skin rash in patients receiving LTG therapy with concomitant VPA
 2. 
To further investigate this observation, we reviewed all case records of adult inpatients with 
refractory epilepsy at the assessment unit of Chalfont Centre for Epilepsy, admitted between 1991 
and 1993, to identify patients who had LTG added to their therapy. We noted whether side effects 
were recorded after its introduction. 
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Of 376 case records reviewed, 103 patients had LTG added to their antiepileptic drug (AED) therapy. 
There were 60 women and 43 men with mean age 35 (range 14 - 54). 
The median starting dose of LTG was 50 mg/day (25-100 mg daily with an incremental dose 
of 25 to 50 mg every one of two weeks). Of 33 patients taking concomitant VPA at a median dose of 
2000 mg/day (600-3000 mg), 13 (39%) developed side effects: 10 (30%) developed skin rash, 2 
(6%) tremor. Of 70 patients not taking concomitant VPA, 13 (19%) developed side effects: 6 (8%) 
of them developed skin rash. 
Statistical analysis using Chi-square test found the difference to be significant at p<0.02 level 
when comparing these two groups for skin rash. The relative risk was 4. 
One patient on VPA, and two not on VPA had florid manifestations with systemic involvement 
which required steroid therapy and 1 patient on VPA and carbamazepine developed a rash and died 
of liver failure. Only 1 patient out of 97 (1 %) had a previous reported skin rash episode on VPA. The 
mean latency to onset of rash was 14 days (range 3-26 days). The median dose of LTG that was taken 
when a rash developed in patients on VPA was 100 mg/day (50-200 mg), and in patients not on VPA 
was 200 mg/day (100-200 mg). 
There was no differential risk of developing an allergic skin rash in patients taking LTG in 
association with carbamazepine, phenytoin, vigabatrin or barbiturates (Table 1). No significant 
difference in risk for skin rash was found comparing patients who had had LTG and VPA with 
concomitant enzyme inducing medication (5/17) to those with LTG and VPA without concomitant 
enzyme inducing medication (5/16). Two patients had their LTG restarted at dose of 6.25 mg/day 
which was slowly increased without recurrence of skin rash. 
The present results have shown significantly higher rate of developing skin rash in patients 
starting LTG taking concomitant VPA when compared to patients starting LTG with other concomitant 
AEDs. The severity of skin rash was variable; 4 of 16 patients were severely affected, requiring 
systemic steroids and hospitalization. 
The aetiology of skin rash induction by LTG is not clear, but appears to be an allergic 
hypersensitivity phenomenon \ Some evidence has suggested that the mechanism of skin rash is 
related to the rate of dosage escalation, with the risk proportional to the initial speed of dosage rise 
Tablel. Incidence of cutaneous rash in 103 patients ** starting lamortrigine. 
RESULTS 
DISCUSSION 34. VPA is known to inhibit LTG metabolism, increasing its serum concentration
s. It is possible that 
in patients on concomitant VPA starting LTG the higher serum concentration of LTG leads to a 
higher risk of skin rash. 
In order to minimise the occurrence of cutaneous rash, it is suggested that LTG should be 
introduced at dose of 25 mg on alternate days with a gradual increase over a period of weeks in 
patients with concomitant VPA therapy, and started at 25 mg/day in patients not taking VPA.Skin 
rash is not an absolute contraindication for reinstitution of LTG, if the patient has benefitted markedly 
from LTG, as we observed no recurrence of skin rash in 2 patients who had LTG reintroduced very 
gradually. Since we have started to introduce LTG at 25 mg on alternate days dosing patients with 
concomitant VPA, we have noted a significant fall in rate of allergic skin rash to LTG. 
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